Updated NETs Clinical Trials

Studies found on ClinicalTrials.gov by a search of: neuroendocrine NOT Melanoma NOT PMS | Recruiting, Not yet recruiting, Available Studies | Phase 2, 3, 4 | Last update posted in the last 30 days

  1. Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

    Condition:   Neuroendocrine Tumors
    Interventions:   Drug: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT;   Drug: CAPTEM (Capecitabine and Temozolomide);   Other: Amino-Acid Solution;   Drug: Everolimus;   Drug: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
    Sponsor:   ITM Solucin GmbH
    Recruiting

  2. Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Metastatic Small Cell Neuroendocrine Carcinomas That Originate Outside the Lung

    Conditions:   Extrapulmonary Small Cell Neuroendocrine Carcinoma;   Recurrent Extrapulmonary Small Cell Neuroendocrine Carcinoma;   Recurrent Small Cell Neuroendocrine Carcinoma;   Small Cell Neuroendocrine Carcinoma
    Interventions:   Biological: Atezolizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Other: Patient Observation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  3. Telotristat With Lutathera in Neuroendocrine Tumors

    Condition:   Neuroendocrine Tumors
    Interventions:   Drug: Telotristat (Low-Dose);   Drug: Telotristat (High-Dose)
    Sponsors:   Aman Chauhan;   TerSera Therapeutics LLC
    Recruiting

  4. Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors

    Condition:   Neuroendocrine Tumors
    Intervention:   Diagnostic Test: 18F-DOPA with furosemide
    Sponsor:   University of Alberta
    Recruiting

  5. Cabozantinib in High Grade Neuroendocrine Neoplasms

    Condition:   High Grade Neuroendocrine Neoplasms
    Interventions:   Drug: Cabozantinib;   Procedure: Blood for plasma biomarkers;   Procedure: Tissue biopsy
    Sponsors:   Washington University School of Medicine;   Exelixis
    Recruiting

  6. Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

    Conditions:   Small-cell Lung Cancer;   Neuroendocrine Carcinoma
    Interventions:   Drug: Iadademstat;   Drug: Paclitaxel
    Sponsors:   Fox Chase Cancer Center;   Oryzon Genomics S.A.
    Not yet recruiting

  7. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015)

    Conditions:   Pheochromocytoma/Paraganglioma;   Pancreatic Neuroendocrine Tumor;   Von Hippel-Lindau Disease
    Intervention:   Drug: Belzutifan
    Sponsor:   Merck Sharp & Dohme LLC
    Recruiting

  8. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

    Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Locally Advanced Pancreatic Neuroendocrine Tumor;   Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Neoplasm;   Metastatic Digestive System Neuroendocrine Tumor G1;   Metastatic Pancreatic Neuroendocrine Tumor;   Metastatic Thymic Neuroendocrine Neoplasm;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Serotonin-Producing Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7;   Unresectable Thymic Neuroendocrine Neoplasm
    Interventions:   Drug: Cabozantinib S-malate;   Procedure: Computed Tomography;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  9. Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

    Conditions:   Neuroendocrine Tumor Grade 3;   Neuroendocrine Carcinoma;   Pancreatic Carcinoma
    Interventions:   Drug: Surufatinib;   Drug: Sintilimab
    Sponsor:   Tianjin Medical University Cancer Institute and Hospital
    Recruiting

  10. Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver

    Conditions:   Pancreatic Neuroendocrine Tumor;   Pancreas Cancer
    Interventions:   Procedure: cytoreductive surgery;   Drug: Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT);   Procedure: Peptide receptor radionuclide therapy (PRRT)
    Sponsor:   University of Chicago
    Not yet recruiting

  11. Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

    Conditions:   Gastroenteropancreatic Neuroendocrine Tumors;   Pheochromocytoma;   Paraganglioma
    Intervention:   Drug: Lutetium [177Lu] oxodotreotide/dotatate
    Sponsor:   Advanced Accelerator Applications
    Recruiting

  12. Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

    Conditions:   Advanced Adrenal Gland Pheochromocytoma;   Advanced Paraganglioma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Paraganglioma;   Unresectable Adrenal Gland Pheochromocytoma;   Unresectable Paraganglioma
    Interventions:   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  13. Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

    Conditions:   Advanced Solid Tumor;   Metastatic Solid Tumor;   Urothelial Cancer;   Poorly Differentiated Neuroendocrine Carcinomas;   Homologous Recombination Deficient-Positive Malignancies Agnostic
    Intervention:   Drug: Lurbinectedin
    Sponsor:   Jazz Pharmaceuticals
    Recruiting

  14. Combination Immunotherapy in Rare Cancers Under InvesTigation

    Conditions:   Advanced Biliary Tract Cancer;   Neuroendocrine Tumors;   Female Reproductive System Neoplasm;   MSI-H Solid Malignant Tumor
    Interventions:   Drug: Ipilimumab;   Drug: Nivolumab
    Sponsors:   Olivia Newton-John Cancer Research Institute;   Bristol-Myers Squibb
    Recruiting

  15. Study of Oral MRT-2359 in Selected Cancer Patients

    Conditions:   NSCLC;   SCLC;   High Grade Neuroendocrine Cancer;   DLBCL;   L-MYC and N-MYC Amplified Solid Tumors;   NSCLC With High or Low L-MYC or N-MYC Expression;   SCLC With High or Low L-MYC or N-MYC Expression
    Intervention:   Drug: Oral MRT-2359
    Sponsor:   Monte Rosa Therapeutics, Inc
    Recruiting

  16. Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults

    Conditions:   Craniopharyngioma, Child;   Craniopharyngioma;   Recurrent Craniopharyngioma
    Interventions:   Drug: Nivolumab;   Drug: DAY101
    Sponsors:   Sabine Mueller, MD, PhD;   Bristol-Myers Squibb;   Day One Biopharmaceuticals, Inc.
    Recruiting

  17. Dose of Magnesium Sulfate Infusion in Obese

    Conditions:   Obese;   Analgesia
    Interventions:   Other: Lactate ringer group;   Drug: Magnesium sulfate dose through real weight group;   Drug: Magnesium sulfate dose through corrected ideal weight group
    Sponsor:   University of Sao Paulo General Hospital
    Recruiting

  18. Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

    Condition:   SCLC, Extensive Stage
    Intervention:   Drug: Atezolizumab
    Sponsors:   AIO-Studien-gGmbH;   Hoffmann-La Roche
    Recruiting

  19. Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity

    Condition:   Obesity
    Interventions:   Drug: Phentermine-Topiramate;   Dietary Supplement: Meal Replacement Therapy;   Other: Placebo
    Sponsor:   University of Minnesota
    Recruiting

  20. 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

    Conditions:   Neuroendocrine Tumors;   Carcinoid Tumor;   Pulmonary Carcinoid Tumor;   Gastroenteropancreatic Neuroendocrine Tumor;   Vipoma;   Insulinoma;   Gastrinoma
    Intervention:   Drug: 177Lu-DOTATOC
    Sponsor:   British Columbia Cancer Agency
    Not yet recruiting

  21. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    Conditions:   Bladder Adenocarcinoma;   Bladder Clear Cell Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Neuroendocrine Carcinoma;   Bladder Small Cell Neuroendocrine Carcinoma;   Bladder Squamous Cell Carcinoma;   Bladder Urachal Adenocarcinoma;   Chromophobe Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Neuroendocrine Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Neuroendocrine Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Urethral Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IV Urethral Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor;   Urethral Clear Cell Adenocarcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  22. Non-Viral TCR Gene Therapy

    Conditions:   Endocrine/Neuroendocrine;   Non-Small Cell Lung Cancer;   Breast Cancer;   Gastrointestinal/Genitourinary Cancers;   Ovarian Cancer
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Aldesleukin;   Biological: Sleeping Beauty Transposed PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  23. A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

    Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Pralsetinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsor:   Hoffmann-La Roche
    Not yet recruiting

  24. A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

    Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Selpercatinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting

  25. Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

    Conditions:   Advanced Cancer;   Anal Carcinoma;   Anal Cancer;   Biliary Cancer;   Cholangiocarcinoma;   Bile Duct Cancer;   Neuroendocrine Tumor;   Carcinoid Tumor;   Endometrial Carcinoma;   Endometrial Cancer;   Cervical Carcinoma;   Cervical Cancer;   Vulvar Carcinoma;   Vulvar Cancer;   Small Cell Lung Carcinoma;   Small Cell Lung Cancer (SCLC);   Mesothelioma;   Thyroid Carcinoma;   Thyroid Cancer;   Salivary Gland Carcinoma;   Salivary Gland Cancer;   Salivary Cancer;   Parotid Gland Cancer;   Advanced Solid Tumors;   Colorectal Carcinoma
    Intervention:   Biological: pembrolizumab
    Sponsor:   Merck Sharp & Dohme LLC
    Recruiting

  26. A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

    Conditions:   Locally Advanced Solid Tumors;   Metastatic Solid Tumors
    Intervention:   Drug: Oral repotrectinib (TPX-0005)
    Sponsors:   Turning Point Therapeutics, Inc.;   Zai Lab (Shanghai) Co., Ltd.
    Recruiting

  27. Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

    Condition:   Metastatic Castration-Resistant Prostate Cancer
    Interventions:   Biological: Pembrolizumab 200 mg;   Drug: Olaparib 400 mg;   Drug: Docetaxel 75 mg/m^2;   Drug: Prednisone 5 mg;   Drug: Enzalutamide 160 mg;   Other: Dexamethasone 8 mg;   Drug: Olaparib 300 mg;   Drug: Abiraterone acetate 1000 mg;   Drug: Lenvatinib;   Biological: Pembrolizumab/Vibostolimab coformulation;   Drug: Carboplatin;   Drug: Etoposide
    Sponsor:   Merck Sharp & Dohme LLC
    Recruiting

  28. Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

    Conditions:   Atypical Teratoid/Rhabdoid Tumor;   Epithelioid Sarcoma;   Kidney Medullary Carcinoma;   Malignant Solid Neoplasm;   Poorly Differentiated Chordoma;   Recurrent Atypical Teratoid/Rhabdoid Tumor;   Recurrent Chordoma;   Recurrent Epithelioid Sarcoma;   Recurrent Kidney Medullary Carcinoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Rhabdoid Tumor;   Refractory Atypical Teratoid/Rhabdoid Tumor;   Refractory Chordoma;   Refractory Epithelioid Sarcoma;   Refractory Kidney Medullary Carcinoma;   Refractory Malignant Solid Neoplasm;   Refractory Rhabdoid Tumor;   Rhabdoid Tumor
    Interventions:   Biological: Atezolizumab;   Procedure: Biospecimen Collection;   Procedure: Computed Tomography;   Other: Fludeoxyglucose F-18;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography;   Biological: Tiragolumab;   Procedure: X-Ray Imaging
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  29. Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients >= 18 Years Old With Advanced Stage Rare Cancers, RARE 2 Study

    Conditions:   Adrenal Gland Pheochromocytoma;   Hematopoietic and Lymphoid System Neoplasm;   Malignant Solid Neoplasm;   Paraganglioma
    Interventions:   Procedure: Computed Tomography;   Drug: Talazoparib;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  30. Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma

    Condition:   Merkel Cell Carcinoma
    Intervention:   Drug: Pembrolizumab
    Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Merck Sharp & Dohme LLC
    Not yet recruiting

  31. Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

    Condition:   Merkel Cell Carcinoma
    Interventions:   Drug: Avelumab;   Radiation: Comprehensive Ablative Radiation Therapy
    Sponsors:   Memorial Sloan Kettering Cancer Center;   EMD Serono
    Recruiting

  32. Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study

    Conditions:   Advanced Renal Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Kidney Medullary Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Papillary Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8;   Unclassified Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radium Ra 223 Dichloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  33. Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

    Conditions:   Adenoid Cystic Skin Carcinoma;   Adnexal Carcinoma;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Apocrine Carcinoma;   Cylindrocarcinoma;   Digital Papillary Adenocarcinoma;   Endocrine Mucin-Producing Sweat Gland Carcinoma;   Extramammary Paget Disease;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Papillary Adenocarcinoma;   Porocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Merkel Cell Carcinoma;   Refractory Mycosis Fungoides;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Skin Squamous Cell Carcinoma;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamoid Eccrine Ductal Carcinoma;   Squamous Cell Carcinoma of Unknown Primary;   Sweat Gland Carcinoma;   Trichilemmal Carcinoma;   Vulvar Squamous Cell Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  34. BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

    Conditions:   Hepatocellular Carcinoma;   Squamous Cell Carcinoma of the Lung;   Merkel Cell Carcinoma;   Myxoid/Round Cell Liposarcoma
    Intervention:   Biological: CAR-GPC3 T Cells
    Sponsors:   SOTIO, LLC;   SOTIO Biotech
    Recruiting